We found no association between GLP-1 RA use and a higher risk of the composite of HF hospitalization or CV death, or HF hospitalizations, which reassures on the safety of these drugs in the setting of T2DM with concomitant HF. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.